A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2015-10

AUTHORS

Robin L. Jones, Johanna C. Bendell, David C. Smith, Konstanze Diefenbach, John Lettieri, Oliver Boix, A. Craig Lockhart, Cindy O’Bryant, Kathleen N. Moore

ABSTRACT

PURPOSE: To characterize the cardiovascular safety profile of regorafenib in patients with advanced cancer. METHODS: Patients received regorafenib 160 mg/day for 21 days followed by a 7-day break. The primary endpoint was the change from baseline in QTcF at the regorafenib t(max) (Day 21, Cycle 1 or 2) and changes in left ventricular ejection fraction (LVEF) from baseline on Cycle 2, Day 21. Secondary objectives were pharmacokinetics, safety, anti-tumor activity and effects on electrocardiogram intervals. QT intervals were corrected using the methods of Fridericia (QTcF) and Bazett (QTcB). LVEF was assessed by multigated acquisition scanning. RESULTS: Fifty-three patients were enrolled, and all received at least one dose of regorafenib 160 mg. Twenty-five patients received regorafenib for 21 days without dose reduction. The mean change from baseline in QTcF at t(max) was (-)2 ms (90 % CI -8, 3). No patient experienced a change from baseline in QTcF > 60 ms, and two had QTcF changes between 30 and 60 ms. No patient had a QTcF or QTcB > 480 ms. In 27 patients who received at least 80 mg of regorafenib, the mean change from baseline in LVEF% ± SD was 1.7 ± 7.8. In 14 patients without a dose reduction, the mean change from baseline in LVEF% was (-)0.1 ± 8.6 at Cycle 2, Day 21. Four patients experienced a LVEF decrease between 10 and 20 %. CONCLUSION: The effects of regorafenib on the QT/QTc interval and LVEF were modest and unlikely to be of clinical significance in the setting of advanced cancer therapy. More... »

PAGES

777-784

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-015-2827-3

DOI

http://dx.doi.org/10.1007/s00280-015-2827-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1039322373

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26281907


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiotoxins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diarrhea", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Eruptions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drugs, Investigational", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Electrocardiography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Ventricles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mucositis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stroke Volume", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Royal Marsden Hospital", 
          "id": "https://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA", 
            "Sarcoma Unit, Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "Robin L.", 
        "id": "sg:person.01110361365.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110361365.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bendell", 
        "givenName": "Johanna C.", 
        "id": "sg:person.01174064377.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174064377.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Michigan Medicine", 
          "id": "https://www.grid.ac/institutes/grid.412590.b", 
          "name": [
            "Internal Medicine Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smith", 
        "givenName": "David C.", 
        "id": "sg:person.015706665604.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015706665604.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bayer (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420044.6", 
          "name": [
            "Bayer Pharma AG, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Diefenbach", 
        "givenName": "Konstanze", 
        "id": "sg:person.01143257300.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143257300.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bayer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.419670.d", 
          "name": [
            "Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lettieri", 
        "givenName": "John", 
        "id": "sg:person.01045704157.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045704157.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bayer (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420044.6", 
          "name": [
            "Bayer Pharma AG, Wuppertal, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boix", 
        "givenName": "Oliver", 
        "id": "sg:person.01320334173.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320334173.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Washington University in St. Louis", 
          "id": "https://www.grid.ac/institutes/grid.4367.6", 
          "name": [
            "Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lockhart", 
        "givenName": "A. Craig", 
        "id": "sg:person.01016673026.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016673026.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Colorado Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.499234.1", 
          "name": [
            "Department of Clinical Pharmacy, University of Colorado Cancer Center, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O\u2019Bryant", 
        "givenName": "Cindy", 
        "id": "sg:person.01204372507.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204372507.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oklahoma", 
          "id": "https://www.grid.ac/institutes/grid.266900.b", 
          "name": [
            "Stephenson Cancer Center, Oklahoma University HSC, Oklahoma City, OK, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moore", 
        "givenName": "Kathleen N.", 
        "id": "sg:person.014355765517.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014355765517.07"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-012-2030-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002023907", 
          "https://doi.org/10.1007/s00280-012-2030-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdn168", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004934309"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(07)61865-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008221380"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.23460", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008652635"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.25864", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013704343"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-04-1443", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014291431"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.6331", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016398351"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2012.153", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016888347", 
          "https://doi.org/10.1038/bjc.2012.153"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-1900", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018407352"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2014.564", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030201307", 
          "https://doi.org/10.1038/bjc.2014.564"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdn019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032320516"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-010-1372-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032910148", 
          "https://doi.org/10.1007/s00280-010-1372-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nbt1068", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036157274", 
          "https://doi.org/10.1038/nbt1068"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nbt1068", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036157274", 
          "https://doi.org/10.1038/nbt1068"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdp025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046459321"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-10", 
    "datePublishedReg": "2015-10-01", 
    "description": "PURPOSE: To characterize the cardiovascular safety profile of regorafenib in patients with advanced cancer.\nMETHODS: Patients received regorafenib 160 mg/day for 21 days followed by a 7-day break. The primary endpoint was the change from baseline in QTcF at the regorafenib t(max) (Day 21, Cycle 1 or 2) and changes in left ventricular ejection fraction (LVEF) from baseline on Cycle 2, Day 21. Secondary objectives were pharmacokinetics, safety, anti-tumor activity and effects on electrocardiogram intervals. QT intervals were corrected using the methods of Fridericia (QTcF) and Bazett (QTcB). LVEF was assessed by multigated acquisition scanning.\nRESULTS: Fifty-three patients were enrolled, and all received at least one dose of regorafenib 160 mg. Twenty-five patients received regorafenib for 21 days without dose reduction. The mean change from baseline in QTcF at t(max) was (-)2 ms (90 % CI -8, 3). No patient experienced a change from baseline in QTcF > 60 ms, and two had QTcF changes between 30 and 60 ms. No patient had a QTcF or QTcB > 480 ms. In 27 patients who received at least 80 mg of regorafenib, the mean change from baseline in LVEF% \u00b1 SD was 1.7 \u00b1 7.8. In 14 patients without a dose reduction, the mean change from baseline in LVEF% was (-)0.1 \u00b1 8.6 at Cycle 2, Day 21. Four patients experienced a LVEF decrease between 10 and 20 %.\nCONCLUSION: The effects of regorafenib on the QT/QTc interval and LVEF were modest and unlikely to be of clinical significance in the setting of advanced cancer therapy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-015-2827-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "76"
      }
    ], 
    "name": "A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer", 
    "pagination": "777-784", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "bb4f9254a4ce1a37ac8070ea47ffc8c3a3356d3b8a3fe0d62c4c47ec700319b3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26281907"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-015-2827-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1039322373"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-015-2827-3", 
      "https://app.dimensions.ai/details/publication/pub.1039322373"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8687_00000514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-015-2827-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-015-2827-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-015-2827-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-015-2827-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-015-2827-3'


 

This table displays all metadata directly associated to this object as RDF triples.

274 TRIPLES      21 PREDICATES      63 URIs      41 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-015-2827-3 schema:about N07ce4457f7fe404e8361953d35c2513e
2 N0c54cac7a38142e3b7f31cd685d810bf
3 N1e418a35d3044faaadad2295d3541eaa
4 N1e86a8e4f4b149a3835ded97b3a75a9a
5 N33442e8ebb1344cc9e1cf5fb581f058c
6 N47a81a5920cb47569e552031b5a98f61
7 N483492b3c87e49c7a99f8eb2486e657a
8 N51a4828811ca4939884a7651ae18ff87
9 N7968cc01314e48258f2c13853df882c9
10 N8bbb8b5e02d947ad8042cff42d86d417
11 N9dcc5c29a90d4568884693709cab1ed5
12 N9ecf51dd862f4ff89819b78e4ae4ee77
13 Na1aaff28b22a47d9b6b74ff6a2a7665a
14 Nbba74ae0a1f44f8cb511d6744bc76cc2
15 Nbd146a07bcf440bc815b3cdd85489c3d
16 Nbdc97ba85b94466cb06d7377f1591969
17 Nd0d5dc6ec55d444bb30745a51b03ae4a
18 Ndd9b2e8d15254ea1a29c520da09a30a1
19 Ne1d5be956a924da59f4d799e81b60325
20 Nffcab10ba52e413b8227a70554f753b9
21 anzsrc-for:11
22 anzsrc-for:1112
23 schema:author N67422dea0b004e1ba5b78cef2116d0ee
24 schema:citation sg:pub.10.1007/s00280-010-1372-3
25 sg:pub.10.1007/s00280-012-2030-8
26 sg:pub.10.1038/bjc.2012.153
27 sg:pub.10.1038/bjc.2014.564
28 sg:pub.10.1038/nbt1068
29 https://doi.org/10.1002/cncr.23460
30 https://doi.org/10.1002/ijc.25864
31 https://doi.org/10.1016/s0140-6736(07)61865-0
32 https://doi.org/10.1093/annonc/mdn019
33 https://doi.org/10.1093/annonc/mdn168
34 https://doi.org/10.1093/annonc/mdp025
35 https://doi.org/10.1158/0008-5472.can-04-1443
36 https://doi.org/10.1158/1078-0432.ccr-11-1900
37 https://doi.org/10.1200/jco.2007.15.6331
38 schema:datePublished 2015-10
39 schema:datePublishedReg 2015-10-01
40 schema:description PURPOSE: To characterize the cardiovascular safety profile of regorafenib in patients with advanced cancer. METHODS: Patients received regorafenib 160 mg/day for 21 days followed by a 7-day break. The primary endpoint was the change from baseline in QTcF at the regorafenib t(max) (Day 21, Cycle 1 or 2) and changes in left ventricular ejection fraction (LVEF) from baseline on Cycle 2, Day 21. Secondary objectives were pharmacokinetics, safety, anti-tumor activity and effects on electrocardiogram intervals. QT intervals were corrected using the methods of Fridericia (QTcF) and Bazett (QTcB). LVEF was assessed by multigated acquisition scanning. RESULTS: Fifty-three patients were enrolled, and all received at least one dose of regorafenib 160 mg. Twenty-five patients received regorafenib for 21 days without dose reduction. The mean change from baseline in QTcF at t(max) was (-)2 ms (90 % CI -8, 3). No patient experienced a change from baseline in QTcF > 60 ms, and two had QTcF changes between 30 and 60 ms. No patient had a QTcF or QTcB > 480 ms. In 27 patients who received at least 80 mg of regorafenib, the mean change from baseline in LVEF% ± SD was 1.7 ± 7.8. In 14 patients without a dose reduction, the mean change from baseline in LVEF% was (-)0.1 ± 8.6 at Cycle 2, Day 21. Four patients experienced a LVEF decrease between 10 and 20 %. CONCLUSION: The effects of regorafenib on the QT/QTc interval and LVEF were modest and unlikely to be of clinical significance in the setting of advanced cancer therapy.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree false
44 schema:isPartOf N9f0b8baa714548a99fbefcc766fffec7
45 Nf573ef3439ce41e4afa60198fd6c556b
46 sg:journal.1088364
47 schema:name A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer
48 schema:pagination 777-784
49 schema:productId N2183eae83226403d912fdc9cf8f40351
50 N3024cfd8ccfb4af8891c923be4fd57f3
51 N4de0f22e6c8d48c28c9fa12bd301e741
52 N517aa4fbcfa248009bd5700d709b1473
53 Nea2d25f8d7eb47159bbb2e68f4fcf85d
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039322373
55 https://doi.org/10.1007/s00280-015-2827-3
56 schema:sdDatePublished 2019-04-10T21:37
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher Nda9097ee04a6461e95db1d56f8f7adc3
59 schema:url http://link.springer.com/10.1007%2Fs00280-015-2827-3
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N006e0919a7e94804a76b7ddd9106abf5 rdf:first sg:person.014355765517.07
64 rdf:rest rdf:nil
65 N07ce4457f7fe404e8361953d35c2513e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Antineoplastic Agents
67 rdf:type schema:DefinedTerm
68 N0c54cac7a38142e3b7f31cd685d810bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Severity of Illness Index
70 rdf:type schema:DefinedTerm
71 N1e418a35d3044faaadad2295d3541eaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Male
73 rdf:type schema:DefinedTerm
74 N1e86a8e4f4b149a3835ded97b3a75a9a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Neoplasms
76 rdf:type schema:DefinedTerm
77 N2183eae83226403d912fdc9cf8f40351 schema:name doi
78 schema:value 10.1007/s00280-015-2827-3
79 rdf:type schema:PropertyValue
80 N2b3adf10172a4e629922e6d709ac784d rdf:first sg:person.01143257300.42
81 rdf:rest Ndb186490b4e64ba99ca6732ddcda790d
82 N2e055a22413c43d789f31b022bcb605b schema:name Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA
83 rdf:type schema:Organization
84 N3024cfd8ccfb4af8891c923be4fd57f3 schema:name readcube_id
85 schema:value bb4f9254a4ce1a37ac8070ea47ffc8c3a3356d3b8a3fe0d62c4c47ec700319b3
86 rdf:type schema:PropertyValue
87 N33442e8ebb1344cc9e1cf5fb581f058c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Drugs, Investigational
89 rdf:type schema:DefinedTerm
90 N47a81a5920cb47569e552031b5a98f61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Drug Eruptions
92 rdf:type schema:DefinedTerm
93 N483492b3c87e49c7a99f8eb2486e657a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Electrocardiography
95 rdf:type schema:DefinedTerm
96 N4b927a92db844055a5a3e67d605de246 rdf:first sg:person.01174064377.38
97 rdf:rest Nb0f03ceabde144b5a62f69f2752ecaff
98 N4de0f22e6c8d48c28c9fa12bd301e741 schema:name pubmed_id
99 schema:value 26281907
100 rdf:type schema:PropertyValue
101 N517aa4fbcfa248009bd5700d709b1473 schema:name dimensions_id
102 schema:value pub.1039322373
103 rdf:type schema:PropertyValue
104 N51a4828811ca4939884a7651ae18ff87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Aged
106 rdf:type schema:DefinedTerm
107 N67422dea0b004e1ba5b78cef2116d0ee rdf:first sg:person.01110361365.31
108 rdf:rest N4b927a92db844055a5a3e67d605de246
109 N7968cc01314e48258f2c13853df882c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Diarrhea
111 rdf:type schema:DefinedTerm
112 N841dd8c28c25412d9485deed46ac4ead rdf:first sg:person.01204372507.27
113 rdf:rest N006e0919a7e94804a76b7ddd9106abf5
114 N8bbb8b5e02d947ad8042cff42d86d417 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Phenylurea Compounds
116 rdf:type schema:DefinedTerm
117 N9dcc5c29a90d4568884693709cab1ed5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Protein Kinase Inhibitors
119 rdf:type schema:DefinedTerm
120 N9ecf51dd862f4ff89819b78e4ae4ee77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Pyridines
122 rdf:type schema:DefinedTerm
123 N9f0b8baa714548a99fbefcc766fffec7 schema:volumeNumber 76
124 rdf:type schema:PublicationVolume
125 Na1aaff28b22a47d9b6b74ff6a2a7665a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Cardiovascular Diseases
127 rdf:type schema:DefinedTerm
128 Nb0f03ceabde144b5a62f69f2752ecaff rdf:first sg:person.015706665604.37
129 rdf:rest N2b3adf10172a4e629922e6d709ac784d
130 Nb45945f8f27f4773a918f8c810b75bc7 rdf:first sg:person.01320334173.88
131 rdf:rest Nbaa283fab75b4b509196ffb7755f18d1
132 Nbaa283fab75b4b509196ffb7755f18d1 rdf:first sg:person.01016673026.04
133 rdf:rest N841dd8c28c25412d9485deed46ac4ead
134 Nbba74ae0a1f44f8cb511d6744bc76cc2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Cardiotoxins
136 rdf:type schema:DefinedTerm
137 Nbd146a07bcf440bc815b3cdd85489c3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Heart Ventricles
139 rdf:type schema:DefinedTerm
140 Nbdc97ba85b94466cb06d7377f1591969 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Female
142 rdf:type schema:DefinedTerm
143 Nd0d5dc6ec55d444bb30745a51b03ae4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Middle Aged
145 rdf:type schema:DefinedTerm
146 Nda9097ee04a6461e95db1d56f8f7adc3 schema:name Springer Nature - SN SciGraph project
147 rdf:type schema:Organization
148 Ndb186490b4e64ba99ca6732ddcda790d rdf:first sg:person.01045704157.46
149 rdf:rest Nb45945f8f27f4773a918f8c810b75bc7
150 Ndd9b2e8d15254ea1a29c520da09a30a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Humans
152 rdf:type schema:DefinedTerm
153 Ne1d5be956a924da59f4d799e81b60325 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Mucositis
155 rdf:type schema:DefinedTerm
156 Nea2d25f8d7eb47159bbb2e68f4fcf85d schema:name nlm_unique_id
157 schema:value 7806519
158 rdf:type schema:PropertyValue
159 Nf573ef3439ce41e4afa60198fd6c556b schema:issueNumber 4
160 rdf:type schema:PublicationIssue
161 Nffcab10ba52e413b8227a70554f753b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Stroke Volume
163 rdf:type schema:DefinedTerm
164 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
165 schema:name Medical and Health Sciences
166 rdf:type schema:DefinedTerm
167 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
168 schema:name Oncology and Carcinogenesis
169 rdf:type schema:DefinedTerm
170 sg:journal.1088364 schema:issn 0344-5704
171 1432-0843
172 schema:name Cancer Chemotherapy and Pharmacology
173 rdf:type schema:Periodical
174 sg:person.01016673026.04 schema:affiliation https://www.grid.ac/institutes/grid.4367.6
175 schema:familyName Lockhart
176 schema:givenName A. Craig
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016673026.04
178 rdf:type schema:Person
179 sg:person.01045704157.46 schema:affiliation https://www.grid.ac/institutes/grid.419670.d
180 schema:familyName Lettieri
181 schema:givenName John
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045704157.46
183 rdf:type schema:Person
184 sg:person.01110361365.31 schema:affiliation https://www.grid.ac/institutes/grid.424926.f
185 schema:familyName Jones
186 schema:givenName Robin L.
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110361365.31
188 rdf:type schema:Person
189 sg:person.01143257300.42 schema:affiliation https://www.grid.ac/institutes/grid.420044.6
190 schema:familyName Diefenbach
191 schema:givenName Konstanze
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143257300.42
193 rdf:type schema:Person
194 sg:person.01174064377.38 schema:affiliation N2e055a22413c43d789f31b022bcb605b
195 schema:familyName Bendell
196 schema:givenName Johanna C.
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174064377.38
198 rdf:type schema:Person
199 sg:person.01204372507.27 schema:affiliation https://www.grid.ac/institutes/grid.499234.1
200 schema:familyName O’Bryant
201 schema:givenName Cindy
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204372507.27
203 rdf:type schema:Person
204 sg:person.01320334173.88 schema:affiliation https://www.grid.ac/institutes/grid.420044.6
205 schema:familyName Boix
206 schema:givenName Oliver
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320334173.88
208 rdf:type schema:Person
209 sg:person.014355765517.07 schema:affiliation https://www.grid.ac/institutes/grid.266900.b
210 schema:familyName Moore
211 schema:givenName Kathleen N.
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014355765517.07
213 rdf:type schema:Person
214 sg:person.015706665604.37 schema:affiliation https://www.grid.ac/institutes/grid.412590.b
215 schema:familyName Smith
216 schema:givenName David C.
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015706665604.37
218 rdf:type schema:Person
219 sg:pub.10.1007/s00280-010-1372-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032910148
220 https://doi.org/10.1007/s00280-010-1372-3
221 rdf:type schema:CreativeWork
222 sg:pub.10.1007/s00280-012-2030-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002023907
223 https://doi.org/10.1007/s00280-012-2030-8
224 rdf:type schema:CreativeWork
225 sg:pub.10.1038/bjc.2012.153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016888347
226 https://doi.org/10.1038/bjc.2012.153
227 rdf:type schema:CreativeWork
228 sg:pub.10.1038/bjc.2014.564 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030201307
229 https://doi.org/10.1038/bjc.2014.564
230 rdf:type schema:CreativeWork
231 sg:pub.10.1038/nbt1068 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036157274
232 https://doi.org/10.1038/nbt1068
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1002/cncr.23460 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008652635
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1002/ijc.25864 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013704343
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1016/s0140-6736(07)61865-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008221380
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1093/annonc/mdn019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032320516
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1093/annonc/mdn168 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004934309
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1093/annonc/mdp025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046459321
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1158/0008-5472.can-04-1443 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014291431
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1158/1078-0432.ccr-11-1900 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018407352
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1200/jco.2007.15.6331 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016398351
251 rdf:type schema:CreativeWork
252 https://www.grid.ac/institutes/grid.266900.b schema:alternateName University of Oklahoma
253 schema:name Stephenson Cancer Center, Oklahoma University HSC, Oklahoma City, OK, USA
254 rdf:type schema:Organization
255 https://www.grid.ac/institutes/grid.412590.b schema:alternateName Michigan Medicine
256 schema:name Internal Medicine Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
257 rdf:type schema:Organization
258 https://www.grid.ac/institutes/grid.419670.d schema:alternateName Bayer (United States)
259 schema:name Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA
260 rdf:type schema:Organization
261 https://www.grid.ac/institutes/grid.420044.6 schema:alternateName Bayer (Germany)
262 schema:name Bayer Pharma AG, Berlin, Germany
263 Bayer Pharma AG, Wuppertal, Germany
264 rdf:type schema:Organization
265 https://www.grid.ac/institutes/grid.424926.f schema:alternateName Royal Marsden Hospital
266 schema:name Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA
267 Sarcoma Unit, Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK
268 rdf:type schema:Organization
269 https://www.grid.ac/institutes/grid.4367.6 schema:alternateName Washington University in St. Louis
270 schema:name Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
271 rdf:type schema:Organization
272 https://www.grid.ac/institutes/grid.499234.1 schema:alternateName University of Colorado Cancer Center
273 schema:name Department of Clinical Pharmacy, University of Colorado Cancer Center, Aurora, CO, USA
274 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...